NRAS and melanoma: LXH254 is being further investigated in combination with a MEK inhibitor (trametinib), an Erk inhibitor (LTT462) or a CDK inhibitor (ribociclib) in patients with NRAS mutant melanoma (NCT02974725, NCT04417621).